Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis

npj Breast Cancer

Article

Chuan Wang¹  Fangmeng Fu¹  Hanxi Chen¹  Qian Nie¹  Xiaobin Chen¹  Minyan Chen¹  Wenhui Guo¹  Wenzhe Zhang¹  Xuan Jin¹  Qindong Cai¹  Lili Chen¹  Yan Li¹  Yuxiang Lin¹  Yazhen Chen²  Xiong Wu²  Fan Wu³  Lin Deng⁴  Long Wu⁵ 

[1] Department of Breast Surgery, Fujian Medical University Union Hospital, 350001, Fuzhou, Fujian Province, China;Department of General Surgery, Fujian Medical University Union Hospital, 350001, Fuzhou, Fujian Province, China;Breast Cancer Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China;Department of Breast Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, 363000, Zhangzhou, Fujian, P.R. China;Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People’s Republic of China;Department of Oncology, No. 900 Hospital of The Joint Logistic Support Force, Fuzhou, China;Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China;

关键词: ;   

DOI  :  10.1038/s41523-023-00552-z

 received in 2022-07-08, accepted in 2023-05-19,  发布年份 2023

来源: Springer

【 摘 要 】

While overweight/obesity has become a major public health issue worldwide, any association between body mass index (BMI) and therapeutic response in neoadjuvant targeted therapy treated HER2 positive breast cancer patients remain unclear. The information from a total of four-hundred and ninety-one neoadjuvant targeted therapy treated HER2 positive breast cancer patients from four institutions were retrospectively collected. Univariate and multivariate logistic analysis was developed to determine the association between BMI and therapeutic response. A meta-analysis of published literature was then conducted to confirm the effect of overweight/obesity on pCR for patients treated with neoadjuvant targeted therapy. Restricted cubic spline (RCS) adjusted for confounding factors demonstrated a decrease pCR with increasing BMI (OR = 0.937, P = 0.045). Patients were then categorized into under/normal weight (n = 299) and overweight/obesity (n = 192). Overweight/obese patients were independently associated with a poor therapeutic response. In the subgroup analysis, a significant negative impact of overweight/obesity on pCR can be observed both in single-targeted (OR = 0.556; P = 0.02) and dual-targeted (OR = 0.392; P = 0.021) populations. Six eligible studies involving 984 neoadjuvant targeted therapy treated HER2 positive breast cancer patients were included in the meta-analysis. The meta-analysis also demonstrated that overweight/obesity was significantly associated with a poor response to neoadjuvant anti-HER2 therapy (OR = 0.68; P = 0.007). Our result show that overweight and obese HER2 positive breast cancer patients are less likely to achieve pCR after neoadjuvant targeted therapy.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6

41116_2023_37_Article_IEq163.gif

41116_2023_37_Article_IEq161.gif

Fig. 1

41116_2023_37_Article_IEq154.gif